Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. It is doubling its API production to have the extra product for sale in Japan.
Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh.
Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.
Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is not an option.
Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use.
Top Japanese drugmakers are moving to sell off their noncore businesses and less profitable generic drugs to focus on new drugs that are protected by patents and that bring in millions more in revenue.
In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.
Eisai's had a rough few years, but it's predicted an upswing in operating profit in the not-too-distant future. And to help it get there, it's struck a new deal in China.
Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.
Biogen has been adding significantly to its manufacturing network lately. Now, it has decided, it is time to subtract.